Fenglei Wu

1.4k total citations
33 papers, 1.1k citations indexed

About

Fenglei Wu is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Fenglei Wu has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 10 papers in Immunology and 9 papers in Oncology. Recurrent topics in Fenglei Wu's work include RNA modifications and cancer (5 papers), RNA Interference and Gene Delivery (4 papers) and MicroRNA in disease regulation (4 papers). Fenglei Wu is often cited by papers focused on RNA modifications and cancer (5 papers), RNA Interference and Gene Delivery (4 papers) and MicroRNA in disease regulation (4 papers). Fenglei Wu collaborates with scholars based in China. Fenglei Wu's co-authors include Shaolin Zhao, Wei Li, Xu Zhang, Zengtao Bao, Haining Li, Ping Zheng, Rutian Li, Baorui Liu, Shengjun Wang and Dawei Cui and has published in prestigious journals such as ACS Applied Materials & Interfaces, Frontiers in Immunology and European Journal of Pharmacology.

In The Last Decade

Fenglei Wu

33 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fenglei Wu China 18 520 300 283 273 175 33 1.1k
Luo‐Qin Fu China 14 403 0.8× 229 0.8× 184 0.7× 171 0.6× 123 0.7× 31 1.0k
Xin Pang China 21 554 1.1× 252 0.8× 284 1.0× 390 1.4× 118 0.7× 40 1.2k
Yufeng Xie China 19 473 0.9× 215 0.7× 261 0.9× 282 1.0× 89 0.5× 38 923
Hassan Dianat‐Moghadam Iran 20 414 0.8× 234 0.8× 356 1.3× 223 0.8× 136 0.8× 43 1.0k
Lingyu Wei China 17 440 0.8× 192 0.6× 268 0.9× 257 0.9× 134 0.8× 31 955
Funan Liu China 20 613 1.2× 140 0.5× 302 1.1× 158 0.6× 170 1.0× 54 1.3k
Chayanon Ngambenjawong United States 10 498 1.0× 472 1.6× 245 0.9× 147 0.5× 103 0.6× 15 1.0k
Maohua Cai China 15 417 0.8× 227 0.8× 267 0.9× 133 0.5× 99 0.6× 19 854
Mohammad Doroudian Iran 25 831 1.6× 297 1.0× 144 0.5× 365 1.3× 195 1.1× 49 1.6k
Weijie Zhang China 16 423 0.8× 214 0.7× 274 1.0× 94 0.3× 232 1.3× 30 1.0k

Countries citing papers authored by Fenglei Wu

Since Specialization
Citations

This map shows the geographic impact of Fenglei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fenglei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fenglei Wu more than expected).

Fields of papers citing papers by Fenglei Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fenglei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fenglei Wu. The network helps show where Fenglei Wu may publish in the future.

Co-authorship network of co-authors of Fenglei Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Fenglei Wu. A scholar is included among the top collaborators of Fenglei Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fenglei Wu. Fenglei Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Nan, et al.. (2024). FTO is Associated with Patient Prognosis and Immune Infiltrates in Gastric Cancer and Regulates TGF-β Expression. Combinatorial Chemistry & High Throughput Screening. 28(11). 1911–1926. 2 indexed citations
2.
Zhao, Luqing, Jianwei Lu, Bo Shen, et al.. (2023). Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study. Frontiers in Oncology. 12. 1036906–1036906. 4 indexed citations
3.
Zhang, Ziting, Min Wu, Nan Hu, et al.. (2022). Enhanced antitumor effect of icariin nanoparticles coated with iRGD functionalized erythrocyte membrane. European Journal of Pharmacology. 931. 175225–175225. 19 indexed citations
4.
Zhang, Ziting, Nan Hu, Xinrui Zhang, et al.. (2022). Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal cancer treatment. Asian Journal of Pharmaceutical Sciences. 17(5). 751–766. 115 indexed citations
5.
Li, Wei, et al.. (2022). Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine & Growth Factor Reviews. 67. 49–57. 98 indexed citations
6.
Hu, Nan, et al.. (2021). A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer. Molecular Therapy — Oncolytics. 24. 148–159. 26 indexed citations
7.
Wu, Fenglei, et al.. (2020). The Role of Chemokine Receptors in Renal Fibrosis. Reviews of physiology, biochemistry and pharmacology. 177. 1–24. 14 indexed citations
8.
Yang, Wen, Wen Feng, Fenglei Wu, et al.. (2020). MiR-135-5p inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by targeting SMAD3 in breast cancer. Journal of Cancer. 11(21). 6402–6412. 17 indexed citations
9.
Huang, Yu, Xinchao Liu, Fenglei Wu, et al.. (2020). Fish Galectin8-Like Exerts Positive Regulation on Immune Response Against Bacterial Infection. Frontiers in Immunology. 11. 1140–1140. 34 indexed citations
10.
Zhang, Dinghu, Yanhong Chu, Hanqing Qian, et al.. (2020). <p>Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer</p>. International Journal of Nanomedicine. Volume 15. 735–747. 40 indexed citations
11.
Chen, Yanyan, Fenglei Wu, Huanying Pang, et al.. (2019). Superoxide dismutase B (sodB), an important virulence factor of Vibrio alginolyticus, contributes to antioxidative stress and its potential application for live attenuated vaccine. Fish & Shellfish Immunology. 89. 354–360. 23 indexed citations
12.
Pan, Xing Q., et al.. (2019). KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma. Tissue and Cell. 61. 44–50. 18 indexed citations
13.
Li, Wei, Xu Zhang, Fenglei Wu, et al.. (2019). Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death and Disease. 10(12). 918–918. 256 indexed citations
14.
Chen, Yanyan, Fenglei Wu, Zhiwen Wang, et al.. (2019). Construction and evaluation of Vibrio alginolyticus ΔclpP mutant, as a safe live attenuated vibriosis vaccine. Fish & Shellfish Immunology. 98. 917–922. 15 indexed citations
15.
Yin, Jun‐Feng, et al.. (2018). Sh-MARCH8 Inhibits Tumorigenesis via PI3K Pathway in Gastric Cancer. Cellular Physiology and Biochemistry. 49(1). 306–321. 21 indexed citations
16.
Hu, Nan, Jun Yin, Puyuan Wu, et al.. (2017). Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine. Cellular Physiology and Biochemistry. 44(6). 2158–2173. 37 indexed citations
17.
18.
Liu, Baorui, Fangbo Cui, Qin Liu, et al.. (2014). Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells. International Journal of Nanomedicine. 9. 2345–2345. 31 indexed citations
19.
Xu, Tongpeng, Canhong Zhu, Jian Zhang, et al.. (2013). MicroRNA-155 Expression has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas. Asian Pacific Journal of Cancer Prevention. 14(12). 7085–7090. 34 indexed citations
20.
Wu, Fenglei, et al.. (2012). Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cellular Oncology. 35(3). 175–180. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luo‐Qin Fu Breakdown of academic impact, for papers by Xin Pang Breakdown of academic impact, for papers by Yufeng Xie Breakdown of academic impact, for papers by Hassan Dianat‐Moghadam Breakdown of academic impact, for papers by Lingyu Wei Breakdown of academic impact, for papers by Funan Liu Breakdown of academic impact, for papers by Chayanon Ngambenjawong Breakdown of academic impact, for papers by Maohua Cai Breakdown of academic impact, for papers by Mohammad Doroudian Breakdown of academic impact, for papers by Weijie Zhang
Rankless by CCL
2026